HCPLive Network

Many Young Patients with Type 1 Diabetes Adopt More Intense Insulin Regimen

 
TUESDAY, Jan. 29 (HealthDay News) -- About half of youths with type 1 diabetes shift to a more intensive insulin regimen over time, which is associated with better glycemic control, according to research published in the January issue of Diabetes Care.

Catherine Pihoker, M.D., of the University of Washington in Seattle, and colleagues examined the patterns and associations of insulin regimens and change in regimens with clinical outcome in a study involving 1,606 youth with recently diagnosed type 1 diabetes.

The researchers found that, during 36 months of follow-up, 51.7 percent of participants changed to a more intensive regimen, 44.7 percent had no change, and 3.6 percent shifted to a less intensive regimen. Younger participants, non-Hispanic whites, and those from families with higher income and parental education and with private insurance were more likely to change to a more intensive regimen or experience no change. Compared with those who changed to a less intensive regimen, those with no change or who changed to a more intensive regimen had significantly lower baseline A1C and smaller increases in A1C over time. The probability of achieving target A1C levels was higher for participants with younger age, continuous subcutaneous insulin pump therapy, and those who changed to a more intensive regimen.

"For the majority of youth in this study, insulin regimen intensified over time, and more intensive regimens were associated with lower A1C," the authors write. "Taking together the better outcomes but sociodemographic disparities in intensification of insulin regimens, there is a dire need to develop strategies to improve care for all children with diabetes."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care.
Results of a recent meta-analysis suggest lower rates of hypoglycemia with insulin degludec in obese patients when compared with insulin glargine.
The American Diabetes Association revised Standards of Medical Care for patients with diabetes include several changes in recommendations regarding testing and treatment goals.
Women with type 1 diabetes experience post-pregnancy deterioration in glycemic control and sustained weight gain, according to research published online Dec. 18 in Diabetes Care.
This podcast is an abstract from the February 2010 issue of The Journal of the American Osteopathic Association about glycemic control in patients with type 2 diabetes.
For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.
Study results presented at ADA 2014 show Eli Lilly’s investigational long-acting basal insulin analog to have similar clinical efficacy in reducing HbA1c levels as a currently approved injectable insulin glargine product, with a comparable side effect profile.
More Reading